期刊
IMMUNOTHERAPY
卷 3, 期 4, 页码 507-516出版社
FUTURE MEDICINE LTD
DOI: 10.2217/IMT.11.18
关键词
ACT; adoptive therapy; cancer immunotherapy; dendritic cell vaccine; T cell
类别
资金
- Cancer Vaccine Institute (London, UK)
- Celgene Corporation
Therapies based on the use of autologous immune cells are among the best candidates for cancer immunotherapy. Dendritic cell vaccines have demonstrated very encouraging responses for some solid tumors, while in melanoma autologous T-cell therapies have exceeded 70% objective response rates in selected Phase I trials. However, it is clear that a number of barriers exist to the effective, practical application of these therapies. The aim of this article is to consider modifications to such strategies over the last 3 years and the resultant clinical research in autologous dendritic cell vaccines, T-cell therapy and gamma delta T-cell therapy for cancer.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据